Summary Multidrug resistance (MDR) to anti-cancer drugs has been associated with the overexpression of Pglycoprotein (P-gp) and the multidrug resistance-associated protein (MRP), both being members of the ATPbinding cassette (ABC) superfamily of transporters. We investigated whether in addition to P-gp and MRP, another ABC transporter, the transporter associated with antigen processing (TAP), is associated with MDR. TAP plays a major role in MHC class I-restricted antigen presentation by mediating peptide translocation over the endoplasmic reticulum membrane. TAP1 and P-gp share a significant degree of homology among their transmembrane domains, which are thought to be the primary determinants of substrate specificity, and both can apparently mediate the translocation of peptides. Using immunocytochemistry and Western blot, TAP was overexpressed in parallel with MHC class I in several MDR human cancer cell lines. TAP was overexpressed more frequently in MRP-positive MDR cell lines (three out of three) than in P-gp positive MDR cells (two out of five). Reversal of resistance resulted in a decrease in TAP levels. Transfection of the TAP genes into TAPdeficient lymphoblastoid T2 cells conferred mild resistance to etoposide, vincristine and doxorubicin (2-to 2.5-fold). Furthermore, etoposide and vincristine inhibited TAP-dependent peptide translocation to the endoplasmic reticulum. Collectively, our results suggest that TAP may modestly contribute to the MDR phenotype, in particular in MRP-overexpressing MDR cells. Further insight into the role of TAP in MDR will require the study of other transfectants, as well as the investigation of TAP expression in P-gp and MRPnegative MDR cancer cell lines.
Through exposure to cytotoxic drugs tumour cells can acquire the so-called multidrug resistance (MDR) phenotype, which is characterised by cross-resistance to structurally and functionally unrelated compounds (Beck and Danks 1991; Gottesman and Pastan 1993) . Evidence is emerging that the molecular basis of MDR is multifactorial. Until now, two proteins that cause MDR have been described: the MDR] gene product P-glycoprotein (P-gp; reviewed in Childs and Ling, 1994) and the MRP gene product multidrug resistanceassociated protein (MRP) (Cole et al., 1992 . Genetic transfer of MDR] or MRP cDNAs showed that the expression of these genes confers resistance to certain unrelated drugs such as doxorubicin, vincristine and etoposide (Childs and Ling, 1994; Cole et al., 1994; Zaman et al., 1994) . P-gp and MRP belong to the ATP-binding cassette (ABC) superfamily of transmembrane transporters, including mammalian (TAP, CTFR, SV2, PMP70), yeast (STE6), and prokaryotic (HlyB) members (Higgins, 1992) . ABC transporters share a structure consisting of two highly conserved cytoplasmic ATP-binding domains and two hydrophobic transmembrane domains (Higgins, 1992) . Proteins of this family are involved in the translocation across biological membranes of a wide range of substrates, ranging in size from metal ions to large proteins. A particular ABC transporter is relatively specific for a given substrate, but a number of these proteins display broad specificity, e.g. P-gp has been implicated in the transport of natural products, calcium channel blockers, calmodulin inhibitors, antibiotics, cations, steroids and chloride (Childs and Ling, 1994; Higgins, 1992 e.g. P-gp and MRP confer a similar MDR phenotype, suggesting similar drug-substrate specificity (Childs and Ling, 1994; Cole et al., 1994; Zaman et al., 1994) . Only a limited number of mammalian ABC transporters have been fully characterised, and further analysis may uncover new transporter-substrate links and cellular functions. Our interest was to investigate whether, besides P-gp and MRP, other(s) ABC transporter(s) may relate to MDR. This possibility was reinforced by the fact that CFTR overexpression has also recently been shown to mediate a MDR phenotype (Wei et al., 1995) . The transporter-associated with antigen processing (TAP), a heterodimer formed by the TAP] and TAP2 gene products, plays a major role in MHC class I (MHCI)-restricted antigen presentation by mediating peptide translocation over the endoplasmic reticulum (ER) membrane (Neefjes et al., 1993) . TAPI and P-gp share a significant degree of homology among their transmembrane domains (Manavalan et al., 1993) , which are thought to be the primary determinants of substrate specificity (Childs and Ling, 1994; Higgins, 1992) . Indeed, P-gp may mediate the translocation of peptides, such as the tripeptide N-acetylleucyl-leucyl-norleucine, ionophores (e.g. gramicidin), cyclic peptides (e.g. cyclosporins) and enkephalins (Higgins, 1992; Sharma et al., 1992; Sarkadi et al., 1994; Eytan et al., 1994) . Based on the analogies between TAP and P-gp, we investigated the potential association of TAP with MDR.
Materials and methods Cell lines
The tumour cell lines and their corresponding drug-selected MDR sublines used in this study have been described previously (reviewed in Beck and Danks, 1991) . The parental lymphoblastoid cell line TI and the mutant T2 cell lines were described by Salter et al. (1985) . T2 cells were derived from Ti and have a large homozygous deletion of the MHC II region (Salter et al., 1985) (Neefjes and Ploegh, 1988) at room temperature for 90 min. After washing in Tris-saline buffer, the sheets were treated with biotinylated goat anti-rabbit antibody followed by streptavidin -horseradish peroxidase (Zymed). The sheets were developed using diaminobenzidine chloronaphtholin. Cell lysates from TI and T2 cell lines were also tested for P-gp and MRP expression using monoclonal antibodies C219 (Centocor, Tongeren, Belgium) and MRPm6 (Flens et al., 1994) respectively. Appropriate MDR cell lines overexpressing P-gp or MRP were used as a positive control.
Cytotoxicity assays Cells in log phase were harvested and plated into 96-well microtitre plates at 3 x 103 cells per well in 100 pl of fresh medium. The plates were incubated at 37°C for 2-3 h. (1993) . Briefly, 1 -1.5 x 106 T2.TAPI +2 cells were washed once with incubation buffer. The plasma membrane of the cells was permeabilised by incubation with 2.5 IU ml-' streptolysin 0 (Wellcome) for 10 min at 37°C. Routinely, 60-80% of the cells were permeabilised as measured by trypan blue uptake. For each assay, 10 pl of radioiodinated model peptide 417, the competing cytotoxic drugs in 50 p1 of incubation buffer and 10 pl of 100 mM ATP pH 7.0 (Boeringer) were added to permeabilised cells in a final volume of 100 pl. Peptide translocation was performed at 37°C over a period of 5 min in order to follow inhibition during the increasing phase of TAP-dependent translocation of the model peptide (Neefjes et al., 1993) . Peptide translocation was stopped by addition of 1 ml of Triton X-100 lysis fluid. Model peptide 417 (sequence: TVNKTERAY) contains an N-linked glycosylation site. After translocation by TAP, the addition of the N-linked glycan takes place in the ER. The glycosylated 417 peptide can then be isolated by concanavalin A-Sepharose (Con A-Sepharose) and quantitated by gamma counting (Neefjes et al., 1993 (Figure 2) . Remarkably, in SW/2R120 cells, reversal of resistance paralleled TAP decrease, as observed in SW/2Rl2ORev cells (2R120 cells cultured without drug for more than 1 year). Increased TAPI levels were seen in the three MRP-positive MDR cell lines tested (SW/2R120, GLC4/ADR and HL60/Adr) and in two of five P-gppositive MDR cell lines (both 8226 sublines). Inhibition by drugs of TAP-dependent peptide translocation The plasma membrane of T2.TAP1 +2 cells was permeabilised by streptolysin 0, and translocation of the radioiodinated model peptide 417 was followed in the presence of different concentrations of the non-radioiodinated 417 peptide and of the competitor drugs. As this assay uses permeabilised cells, the system used to test TAP-mediated translocation of peptides requires the presence of the TAP protein, ATP and intact glycosylation machinery within the ER, but not cytosolic factors. Therefore, any observed inhibitory effect of peptide translocation is most likely specific via direct interaction with TAP (Neefjes et series (data not shown; see Table I) . A low TAP1 level was present in the 2R12ORev cell line. Figure 3) . As shown in Figure 4 , increasing amounts of input peptide indeed results in a higher recovery of translocated peptide. The inhibitory effect of etoposide was similar at the different concentrations of radiolabelled input peptide. These results indicate that the inhibition of TAP-mediated transport of peptides by drugs is most likely due to specific interaction with TAP. Competitor (gM) Figure 3 Etoposide, vincristine and doxorubicin were tested for their ability to compete for translocation of the radiolabelled model peptide 417 in streptolysin 0-permeabilised T2.TAP1 + 2 transfectants. Translocation was followed for 5min at 37°C in the presence of ATP. The cells were lysed, and the radiolabelled 417 was recovered with Con-A-Sepharose and quantitated by gamma counting. Fifty per cent inhibition was observed with etoposide (-400pM), vincristine (-2.5mM) and non-radiolabelled 417 There is in vitro and in vivo evidence that down-regulation of TAP, and therefore of peptide transport and MHC I expression, may be a mechanism by which tumours escape immune surveillance (Cromme et al., 1994; Restifo et al., 1993) . We show that in some cancer cell lines TAP is coordinately up-regulated with MHC I in response to cytotoxic drug selection. Further studies on the TAPmediated effect of cytotoxic drug treatment for augmenting MHC I expression may result in novel approaches to facilitate cytotoxic T-cell mediated immunotherapies.
In al., 1992; Neefjes et al., 1993; Salter et al., 1985) .
Commonly, resistance for MDRJ or MRP transfectants has been measured after the transfectants were selected on chemotherapeutic drugs. Levels of resistance for true MDR1, MRP or CFTR cDNA transfectants (non-chemotherapeutic drug-selected transfectants) and infectants range typically from 2-to 10-fold Guild et al., 1988; Wei et al., 1995; Zaman et al., 1994) . Non-drug selected murine MDRI retroviral-mediated infectants were found to be 42.7-fold resistant to doxorubicin (mean 1.3-fold), vinblastine (mean 1.7-fold) and colchicine (mean 1.4-fold) (Guild et al., 1988) . Recently, overexpression of another ABC transporter, the cystic fibrosis transmembrane conductance regulator (CFTR) gene, has been shown to be associated with a MDR phenotype (Stutts et al., 1993; Wei et al., 1995) . Transfection of the CFTR cDNA into NIH3T3 cells resulted in increased levels of resistance to doxorubicin and vincristine that were similar to those that we measured here for TI and T2.TAP1 + 2 cells (Stutts et al., 1993; Wei et al., 1995) .
The drug inhibition of TAP-mediated transport of peptides adds further support to the theory of interaction between certain drugs and the TAP protein. The drugs we tested interact with TAP with much lower affinity than the model peptide 417, which is known to be translocated very efficiently by TAP, and in that sense is a biased strong competitor (Neefjes et al., 1993) . Peptides with 50 to 100-fold lower affinity are also translocated and presented within MHC I, indicating that they are functional (Neisag et al., 1995 Marquardt and Center, 1992) . We did not find obvious differences in the intracellular distribution of fluorescent daunorubicin between TI or T2.TAP1 + 2 cells and T2 cells (data not shown), but this analysis was largely complicated by the small size and reduced cytoplasmic area of these lymphoblastoid cells.
TAP was up-regulated in all three MRP-overexpressing MDR cell lines that we tested, but only in two (both 8226 sublines) of five P-gp-positive MDR cell lines. We have previously reported a similar pattern of MRP overexpression in TAP-overexpressing MDR cell lines (Flens et al., 1994) . In the SW-1573 series, TAP and MRP expression are closely parallel, showing up-regulation in the 2R120 cells and downregulation to parental levels in 2R120 Rev and 2R160 cells (Flens et al., 1994) . In this series, we calculated the staining index for MRP, as described in Materials and methods, using the monoclonal antibody MRPm6 (see footnote to Table I ). The staining index for TAP and MRP were strongly correlated (coefficient of correlation, r2 = 0.94), suggesting that they are not only qualitatively but also quantitatively coregulated. This sort of frequent co-regulation of two mammalian ABC transporters, such as TAP and MRP, in response to a single cellular insult is without precedent among other members of this superfamily (Higgins, 1992) . A plausible explanation for this close association is that both MRP and TAP contribute to the high levels of MDR observed in drug-selected MDR cells. Thus, it has been shown that MRP overexpression or changes in topoisomerase II activity cannot account for the MDR phenotype observed in the P-gp-negative 2R120 and GLC4/ADR cells, in which the role of an additional mechanism(s) has been proposed (Kuiper et al., 1990; Zijlstra et al., 1987) . TAP seems to be a good candidate. Why TAP appears to be less frequently upregulated in P-gp-positive MDR cell lines remains unclear.
Another possibility for the joing up-regulation of TAP and MRP, and less frequently of TAP and P-gp, is that different ABC transporters share similar transcription machinery (i.e. similar transcription factors or promoter regions). This possibility could be further investigated by measuring mRNA levels and/or rates of transcription in nuclear runon experiments.
In conclusion, we have shown TAP overexpression in cancer cell lines selected in the laboratory for MDR phenotype, and have provided additional data supporting the capacity of TAP to confer drug resistance. Further insight into the potential contribution of TAP to MDR, and into the functional significance of TAP-MHC I overexpression in MDR cancer cell lines may require the study of other TAP] + 2 transfectants, the specific suppression of TAPJ/2 gene expression in TAP-overexpressing MDR cells, as well as the study of TAP expression in Pgp-and MRPnegative MDR cancer cell lines (Takeda et al., 1994; Slapak et al., 1994) .
